Analyse MiniMed Group, Inc. (MMED) — Kairos Score 66/100

À propos de MiniMed Group, Inc.

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 0 achats et 0 ventes déclarés par les dirigeants de MiniMed Group, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur MMED dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur MMED.

• Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
• Why Medtronic’s $4 Billion MiniMed Exchange Offer Is Losing Its Allure

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.